193 related articles for article (PubMed ID: 19818997)
1. Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers.
Li AJ; McAllister P; Karlan BY
Gynecol Oncol; 2010 Jan; 116(1):105-8. PubMed ID: 19818997
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas.
Li AJ; Scoles DR; Armstrong KU; Karlan BY
Gynecol Oncol; 2008 May; 109(2):220-5. PubMed ID: 18374401
[TBL] [Abstract][Full Text] [Related]
3. Androgen mediation of thrombocytosis in epithelial ovarian cancer biology.
Li AJ; Karlan BY
Clin Cancer Res; 2005 Nov; 11(22):8015-8. PubMed ID: 16299230
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype.
Dagan E; Friedman E; Paperna T; Carmi N; Gershoni-Baruch R
Eur J Hum Genet; 2002 Nov; 10(11):724-8. PubMed ID: 12404104
[TBL] [Abstract][Full Text] [Related]
5. Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology.
Li AJ; Elmore RG; Pavelka JC; Karlan BY
Gynecol Oncol; 2007 Dec; 107(3):420-3. PubMed ID: 17825390
[TBL] [Abstract][Full Text] [Related]
6. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series.
Levine DA; Boyd J
Cancer Res; 2001 Feb; 61(3):908-11. PubMed ID: 11221880
[TBL] [Abstract][Full Text] [Related]
7. Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma.
Li AJ; Baldwin RL; Karlan BY
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3667-73. PubMed ID: 14506156
[TBL] [Abstract][Full Text] [Related]
8. Polymorphic CAG repeat length within the androgen receptor gene: identification of a subgroup of patients with increased risk of ovarian cancer.
Santarosa M; Bidoli E; Gallo A; Steffan A; Boiocchi M; Viel A
Oncol Rep; 2002; 9(3):639-44. PubMed ID: 11956643
[TBL] [Abstract][Full Text] [Related]
9. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
10. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
[TBL] [Abstract][Full Text] [Related]
11. CAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer.
Kim SC; Ju W; Mahavni V; Geisler JP; Buller RE
Int J Gynecol Cancer; 2006; 16 Suppl 1():190-4. PubMed ID: 16515589
[TBL] [Abstract][Full Text] [Related]
12. Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
Kim YT; Nam EJ; Yoon BS; Kim SW; Kim SH; Kim JH; Kim HK; Koo JS; Kim JW
Gynecol Oncol; 2005 Dec; 99(3):585-90. PubMed ID: 16084575
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor gene cytosine, adenine, and guanine trinucleotide repeats in patients with endometriosis.
Lattuada D; Viganò P; Somigliana E; Odorizzi MP; Vignali M; Di Blasio AM
J Soc Gynecol Investig; 2004 May; 11(4):237-40. PubMed ID: 15120698
[TBL] [Abstract][Full Text] [Related]
14. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
[TBL] [Abstract][Full Text] [Related]
15. Improved survival in women with BRCA-associated ovarian carcinoma.
Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
[TBL] [Abstract][Full Text] [Related]
16. Shorter CAG repeat length in the AR gene is associated with poor outcome in head and neck cancer.
Rosa FE; dos Santos RM; Poli-Frederico RC; Canevari Rde A; Nishimoto IN; Magrin J; Rainho CA; Kowalski LP; Rogatto SR
Arch Oral Biol; 2007 Aug; 52(8):732-9. PubMed ID: 17321486
[TBL] [Abstract][Full Text] [Related]
17. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.
Brozek I; Ochman K; Debniak J; Morzuch L; Ratajska M; Stepnowska M; Stukan M; Emerich J; Limon J
Gynecol Oncol; 2008 Feb; 108(2):433-7. PubMed ID: 17997147
[TBL] [Abstract][Full Text] [Related]
18. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.
Werness BA; Ramus SJ; DiCioccio RA; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; Tsukada Y; Harrington P; Gayther SA; Ponder BA; Piver MS
Int J Gynecol Pathol; 2004 Jan; 23(1):29-34. PubMed ID: 14668547
[TBL] [Abstract][Full Text] [Related]
19. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
Rubin SC; Benjamin I; Behbakht K; Takahashi H; Morgan MA; LiVolsi VA; Berchuck A; Muto MG; Garber JE; Weber BL; Lynch HT; Boyd J
N Engl J Med; 1996 Nov; 335(19):1413-6. PubMed ID: 8875917
[TBL] [Abstract][Full Text] [Related]
20. Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome.
Ludwig AH; Murawska M; Panek G; Timorek A; Kupryjanczyk J
Endocr Relat Cancer; 2009 Sep; 16(3):1005-16. PubMed ID: 19458022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
